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Methods:  We  report  trends  and patterns  of  percutaneous  cardiovascular  interventions  (PCI)  by region  for
2005–2009,  with  more  detailed  data  on management  of  myocardial  infarctions  in 2009–2103,  relating
them  to regional  economic  development  and changes  in  mortality  from  myocardial  infarction.
Results:  PCIs  per  100,000  population  increased  from  8.7 in  2005–71.3  in 2013,  with  considerable  regional
variation.  In 2013  the  highest  rates  were  in  the wealthiest  regions,  although  not  in some  remote  regions
dependent  on  oil  and  mineral  extraction.  Between  2009  and  2013 rates  of  thrombolysis  in  those  with
acute  myocardial  infarctions  potentially  eligible  for treatment  remained  broadly  similar  at about  28%  but
rates  of  primary  revascularisation  with  stenting  rose  rapidly,  from  6.5%  to  23.7%.  In-hospital  mortality
from  myocardial  infarction  since  2009  has  declined  most  in  regions  achieving  highest  rates  of  primary
revascularisation.
Conclusions:  The  sustained  investment  in  advanced  cardiovascular  technology  has  been  associated  with
substantial  increases  in revascularisation  in  some  but not  all  regions.  However,  rates  overall  remain  far
behind  those  in Western  Europe.  Further  research  is in  progress  to  understand  the  reasons  for  these
variations  and  the  barriers  to  further  expansion  of services.
©  2017  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the  CC  BY
license  (http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Cardiovascular disease mortality has been declining in nearly
all high income countries for many decades [1]. These declines,
beginning as early as the 1960s in some countries, have reﬂect both
reduction in risk factors and improved primary and, most recently,
secondary prevention [2]. Today in well-resourced settings, some-
body who has a heart attack is more likely to survive than in
the past, due to widely available medical interventions, includ-
ing timely non-invasive percutaneous cardiovascular interventions
(PCI) such as balloon angioplasty [3,4], in which an atherosclerotic
occlusion of the coronary artery is opened through inﬂation of a
small balloon. This was introduced in the 1980s [5] and, initially,
was mainly an elective procedure for people with symptomatic
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coronary artery disease [6], alongside coronary artery bypass graft-
ing (CABG) which also became common at that time [7]. The
extension of PCI to insert a stent, to keep the artery from clos-
ing up again, started to be introduced into routine practice in the
1990s. Today it is commonly used as the primary intervention in
acute myocardial infarction. There is now good evidence that these
primary reperfusion interventions result in better outcomes than
thromobolysis [8] and, in many countries, there is now a switch
from thrombolysis to PCI for ST-elevation myocardial infarctions
(STEMI), although progress is variable [9,10]. Yet while these min-
imally invasive procedures are now relatively straightforward to
perform, they still require a substantial initial investment in equip-
ment and training of expert staff.
Access to new treatments for ischemic heart disease is high
on the agenda in the Russian Federation, where mortality from
cardiovascular disease has been falling since 2005/6 although it
remains among the highest in the world. In a speech on September
5, 2005, Russian President Vladimir Putin announced four national
priority projects, including one focussed on improving popula-
tion health. A council to implement the projects was established,
https://doi.org/10.1016/j.healthpol.2017.09.018
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initially headed by Putin himself and subsequently by Prime Min-
ister Dmitry Medvedev, involving enhanced cooperation between
federal, regional and local governments, non-governmental organ-
isations, and research institutes. The health project sought to
decrease the burden of disease, improve accessibility to high-
quality health care, develop a prevention-oriented health care
system, increase the role of primary and ambulatory care, and
increase the provision of advanced medical technology. In 2008, a
speciﬁc goal to reduce mortality from cardiovascular diseases was
added. Increased funding was made available to improve salaries
of health professionals and purchase new equipment, with federal
expenditure increasing from 87.9 billion roubles in 2006–160.2 bil-
lion roubles in 2010. Initially it was planned that 80% of funds would
go to primary care and disease prevention, with the 20% going
to advanced medical technology. However, during the course of
implementation, this shifted to a 55%/45% split. [11]
The project did much to address the long-term underinvestment
in advanced medical technology in Russia. The ﬁrst evaluation of
the implementation of the project, in 2007, reported that 680,000
health workers had received increased salaries, 13,500 primary care
physicians had undergone retraining, waiting times had reduced,
and over 5500 health facilities had been re-equipped.
Its implementation has coincided with the decline in mortal-
ity from cardiovascular disease in Russia noted above. However,
the role that the various federal initiatives may  have played in this
decline is uncertain. One study using registry data from regions
acquiring new percutaneous cardiovascular intervention (PCI) cen-
tres has reported a decline in-hospital mortality [12] but otherwise
there is little information on the results of the investment in
advanced specialist equipment across the whole country.
In this paper, we use the available data to assess, to the extent
possible, how far the investment in specialist cardiological equip-
ment has resulted in increased numbers of PCIs (a measure of
process). In addition we investigate whether at a regional level
there is an association between expansion in PCI activity and
changes in-hospital mortality from acute myocardial infarction
among MI  patients admitted to hospital in the Russian Federation.
2. Methods
Data on hospital activity and outcomes were obtained from the
Federal Research Institute for Health Organization and Informatics
of Ministry of Health of the Russian Federation. It is responsible
for collating data from all Russian public hospitals, each of which
is required to make regular statistical returns that are assembled
initially at the regional level. These data are supplied to the Insti-
tute in the form of tabular data. Hospitals in Russia are organised
in a territorial basis, at regional and federal level, with increasing
levels of specialisation. In 2008, only 124 of the 6545 hospitals in
Russia were privately owned and these hospitals are also required
to make statistical returns. Thus, we believe that the data provide
a relatively comprehensive picture of activity across the country.
We were provided with information collected on State Statistic
Form 14 “Data on hospital functioning” for the years 2005–2013.
This included the total number of invasive cardiovascular pro-
cedures, both Percutaneous Transluminal Coronary Angioplasty
(henceforth referred to simply as PCI) and coronary artery bypass
grafting (CABG). For the years 2009–2013 more detailed infor-
mation was available, comprising numbers of patients with
myocardial infarction (patients whose diagnosis was coded as ICD-
10 I21) admitted within 12 or 24 h of symptom onset and who
received thrombolysis or PCI with stenting. We  present results
according to two levels of geographic aggregation as deﬁned in
2013: the 8 federal districts or the 83 constituent regional admin-
Fig. 1. Trends in PCI/100,000 population by Russian federal district 2005–2013.
istrative regions, generally known as oblasts (Box). None of these
data are broken down by age and sex.
Given the limitations of these data we  adopted a pragmatic def-
inition whereby patients deemed potentially eligible for either of
these interventions were those admitted within 12 h of symptom
onset, although of course this will include a variable proportion
who are ineligible because of delay or contra-indications. Data on
population and gross regional product of the regions of the Rus-
sian Federation were obtained from the State Statistical Committee,
Rosstat.
We analysed time trends in rates of PCI per 100,000 popu-
lation for the period 2005–13. We  also analysed trends in the
proportion of myocardial infarctions subject to PCI with stenting
within 12 h of onset for the period 2009–13. We also investigated
whether this progress was associated with the economic wealth
of the region. Finally, we sought to determine if there was any
association between greater use of primary revascularisation for
myocardial infarction within 12 h of onset and in-hospital mortal-
ity. As noted, we  only had data on these acute interventions from
2009, although we  know that, outside a few large cities such as
Moscow, it was very uncommon prior to this. Thus, it was not pos-
sible to correlate changes in acute stenting and mortality at regional
level over this entire period. As a pragmatic alternative, recognising
that rates were almost universally close to zero in 2005, we divided
the regions into 4 categories, based on the rate of primary revas-
cularisation in 2013 (following exclusion of those admitting fewer
than 500 patients/year within 12 h of symptom onset). We then
regressed in-hospital mortality by year between 2005 and 2013
in each of these regional groupings and modelled the impact on
mortality from the resulting equations.
Data analyses were undertaken using SPSS. ArcGIS was  used to
visualise geographic variation in rates.
3. Results
The number and rates per 100,000 population of myocardial
infarctions admitted to hospital within 24 h of onset and both PCI
and coronary artery bypass grafting (not further considered) by
year in the Russian Federation as a whole is shown in Table 1, for
each year between 2005 and 2013.
The number of PCIs has risen markedly, but at different rates
per head of population across the country. Fig. 1 shows the trends
in procedures in the eight federal districts. All had rates below
15/100,000 in 2005 but, by 2013, the north-western federal dis-
trict, which covers the area from St Petersburg to the Urals, had
achieved a rate of over 120/100,000, while in the North Caucasus it
was only 20/100,000, an over a 6-fold variation.
A more detailed picture of geographic variation in the rate of PCI
procedures is provided in Fig. 2, which maps rates at the level of
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Table 1
Trends in numbers and rates/100,000 population of admissions for myocardial infarction (MI) (ICD-10 I21) and selected interventions: Russian Federation.
2005 2006 2007 2008 2009 2010 2011 2012 2013
Numbers
MI  admissions 163,301 162,58,1 161,789 161,257 162,535 155,334 152,022 152,151 156,818
PCI  12,21 8 19,426 26,296 33,872 43,129 50,390 63,412 81,416 99,664
CABG  9999 12,029 13,913 17,790 20,836 23,184 27,016 29,214 28,717
Rates/100,000
MI  admissions 116.7 116.2 115.7 115.3 116.2 111.1 108.7 108.8 112.1
PCI  8.7 13.9 18.8 24.2 30.8 36.0 45.3 58.2 71.3
CABG  7.1 8.6 9.9 12.7 14.9 16.6 19.3 20.9 20.5
Note: CABG − coronary artery bypass grafting.
Fig. 2. Rate of angioplasty/100,000 population in Russian regions in 2013 (top) and the absolute change between 2005 and 2013 (bottom).
regions (oblasts), divided into approximate ﬁfths. In 2005 only ﬁve
regions were undertaking more than 30 PCI per 100,000 (Moscow
City, Krasnoyarsk, Tomsk, Murmansk and Tyumen). However, in
2013, 13 regions, including some of the poorest and most remote
in the Far North, Far East or North Caucasus still reported no proce-
dures. The four highest rates in 2013 were in Novosibirsk (Russia’s
third-largest city and a medical and scientiﬁc research), Moscow,
Magadan (in the Far East), and St Petersburg, with 241, 226, 225,
and 223 procedures per 100,000 respectively.
Intuitively, it seems likely that low population density would
constrain increases in uptake. However, this is very difﬁcult to
assess with aggregate data as, in the larger regions, the population is
often concentrated in a few settlements. Thus, there is no signiﬁcant
association between population density and the slope of the annual
increase PCI rate between 2009 and 2013 (after removal of Moscow
and St Petersburg that are clear outliers) (r = 0.180, p = 0.107). How-
ever, there is a signiﬁcant association with wealth and the increase
in uptake (Fig. 3) (r = 0.272, p = 0.013), although there are several
clear outliers. The outlying wealthy regions with no or few proce-
dures are sparsely populated mineral rich lying in the far north,
such as the Yamalo-Nemets region, with a population of 500,000
in an area 20% larger than France, which produces 90% of Russia’s
natural gas.
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Fig. 3. Association between annual increase in PCI/100,000 population (2005–2013) and gross regional product in Russian regions.
Fig. 4. Trends in-hospital mortality following acute myocardial infarction in Russian
federal districts.
We  now turn to the management and outcome of acute myocar-
dial infarction, noting that we only have data for 2009–2013. As
noted in the introduction, this has been transformed in recent
decades, especially following the introduction of thrombolysis and
more recently primary revascularisation using PCI. Rates of throm-
bolysis in hospitals have remained broadly similar during this
period (Appendices), with 28.8% of patients with myocardial infarc-
tion admitted within 12 h in being given thrombolysis the Russian
Federation as a whole in 2013 (from 27.9% in 2009). In contrast,
there has been a steep increase in rates of primary revascularisa-
tion with stenting for which the corresponding ﬁgures were 6.5%
in 2009 and 23.7% in 2013. However there is wide variation of over
three-fold in 2013 between the highest and lowest performing Fed-
eral Districts and, by 2013 about two-thirds of potentially eligible
patients were not undergoing revascularisation, although the data
do not allow us to determine how many received thrombolysis
instead. Among the individual regions, there is very wide variation
(Appendices) for both treatments.
Turning to outcomes, as Fig. 4 shows, there has been a decline in-
hospital mortality. This coincided with a decline of 0.9% per year in
the number of patients with myocardial infarction admitted to hos-
pital over this period, consistent with the previous research cited
above which noted the overall decline in cardiovascular deaths. The
decline began in 2009. However, as this ﬁgure relates to in-hospital
rather than over a ﬁxed period (e.g. 30 days) some of this reduction
could be due to a fall in average length of stay by patients with
myocardial infarction.
The reduction in-hospital mortality was  greatest in those
regions achieving higher stenting rates (although the decline did
not reach statistical signiﬁcance in hospitals achieving stenting
rates of 15–25% (Appendices).
4. Discussion
4.1. What is already known?
The high political priority placed on tackling cardiovascular
disease in the Russian Federation reﬂects its great human, eco-
nomic and social costs [13,14]. Since the mid-2000s there has been
considerable progress in reducing cardiovascular mortality. Most
attention has focused on two factors that have contributed to this
achievement. The ﬁrst is the reduction in the high rate of alcohol-
related mortality, which in post-Soviet countries includes many
cardiovascular deaths, in particular sudden cardiac death [15]. This
seems at least partly attributable to increased prices and measures
to reduce supply [16], although deliberate alcohol control policies
may  not be the entire story [17]. The second is improved man-
agement of a range of conditions amenable to health care, such as
diabetes and infections but also hypertension, thought to explain
at least some of the decline in cardiovascular disease, especially
among older women  and reﬂecting, primarily, improved primary
care and better access to medicines. However, so far, little attention
has been paid to the substantial investment in advanced cardiovas-
cular treatment, either to ascertain how it has changed treatment or
whether it has improved outcomes, as might be expected given evi-
dence from recent meta-analysis conﬁrming improved outcomes
associated with primary percutaneous intervention following acute
coronary syndrome [18].
4.2. What this study adds
This is, to our knowledge, the ﬁrst attempt in the interna-
tional literature to undertake a quantitative assessment of the
achievements of the Russian federal public health programme and,
speciﬁcally, that element of it intended to increase access to spe-
cialised care for cardiovascular disease.
Judged by process measures, the Russian Health programme
has been effective, with substantial increases in intervention rates
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since 2005. Revascularisation is now being undertaken in many
places where it was previously absent. However there are still
many regions lacking any provision. The management of acute
myocardial infarction has also changed in many regions, with
a marked expansion in primary revascularisation, although it
remains unavailable in some regions. This mixed picture is consis-
tent with a mid-term qualitative assessment that concluded that,
while spending had increased, adding about 10% to the overall
health budget, the programme had placed too much emphasis on
initial capital investment without taking account of the need to
train staff and fund revenue costs, including consumables [19].
It is more difﬁcult to reach any conclusion on health outcomes.
It does seem that in-hospital mortality has declined most in those
regions that have achieved the highest intervention rates. However,
further analysis is limited by the absence of individual level data.
There are few other data from Russia available for comparison
but the international CLARIFY study, which includes 2200 patients
from across Russia, reports a low frequency of revascularisation
compared to other countries [20]. The RECORD study, a low cost
internet based study, reported data from 14 hospitals in 2007/8
[21], with 32.1% of patients with ACS receiving thrombolysis while
18.7% received primary PCI [21]. Subsequent, so-far unpublished
data from 2009 to 2011 report an increase in primary PCI to 39%
but thrombolysis remaining the same, at 32%. The Russian Acute
Coronary Syndrome register, operating in 23 regions [22], reported
that the rate of PCI for ACS increased from 22% in 2009–2011 to 28%
in 2012 [23].
Unfortunately, only a few international comparisons include
Russian data, and to a limited extent [24], while others exclude
Russia entirely [25]. However, comparison with published data
from elsewhere illustrate the gap that remains. Comprehensive
registry studies show much higher rates of primary revasculari-
sation in Sweden (75.9%) and the United Kingdom (80.6%) in 2010
[26] although, in Europe as a whole, large variations persist, with
southern and eastern Europe still achieving relatively low rates
[25].
These differences, in part, may  reﬂect the different starting
points. PCI procedures in countries such as the United Kingdom
have been increasing since the early 1990s, much longer than in
Russia. However, there are clearly other factors; research on the
increase of PCI utilization in 10 European countries has identiﬁed
the role played by numbers of physicians and other health workers
and of hospital beds, both of which are high in Russia. In contrast,
the increase was also greatest where the population density was
highest, which is not the case in most of Russia [27]. Finally, while
comparisons are problematic, it is notable that rates of in-hospital
mortality in Russia are appreciably higher than the 30-day mortal-
ity observed in the UK (8%) and Sweden (11%) [28].
4.3. Limitations
It is important to recognise the limitations of this study.
Although there has been a signiﬁcant investment in data collec-
tion in the Russian Federation in recent years, its systems still lag
far behind those that are in place in many Western countries. Con-
sequently, we were only able to analyse aggregate statistics at a
regional level rather than data at the level of the hospital or the
individual. The absence of data cross-tabulated by age is a particular
limitation, especially when comparing across regions or countries.
A further challenge is that, during the period that these data relate
to, a number of regions have merged, in each case involving some
of the largest geographical areas but with the smallest populations,
most of whom are highly concentrated in a few settlements.
As with all studies using routine administrative data, consider-
able caution is required in interpretation. Diagnosis of myocardial
infarctions would have been based on routine clinical procedures
rather than on the standardised case deﬁnitions that might be used
in a clinical trial, for example. However, at least for the last ﬁve
years, troponin tests have been widely available.
As is the case everywhere, it is likely that there are some inac-
curacies in the data. However, the returns are relatively simple,
tabulating numbers of patients and procedures, and are subject to
veriﬁcation processes at each administrative level.
Finally, this paper only considers activity in hospitals. Especially
in the more remote areas, there will be patients with myocardial
infarction who do not reach hospital. Although the Russian Fed-
eration inherited a health system that provided at least basic care
to a highly dispersed population, there are still many parts of the
country where it can take several days to reach a hospital, simply
because the distances are so vast, the climate harsh, and the trans-
port infrastructure correspondingly limited [29]. Thus, Krasnoyarsk
Krai extends from the Arctic Ocean almost to the Mongolian bor-
der. Occupying almost 1,000,000 km2, it has a population of 2.8
million people, a million of whom live in the regional capital in
the south. On the basis of population-level data from Quebec, with
a similar geography, there is likely to be substantial variation in
revascularisation within these large regions [30].
5. Conclusion
This study shows that there has been considerable progress in
improving access to high technology care in the Russian Federa-
tion coinciding with the substantial investment within the federal
health programme. However, progress has been mixed and has
been greatest in the major cities and lowest in the poorest regions
or those which, while wealthy as judged by ofﬁcial statistics, have
economies based on extractive industries. Unfortunately, with the
data available to us at present, our ability to explain this variation
is constrained. However, on the basis of our ongoing research, it
is possible to make some observations. First, in some parts of the
Russian Federation it is not only difﬁcult for patients to reach hos-
pital. It is also extremely difﬁcult to attract and retain specialist
clinical staff. It is notable that many of the regions that are still
failing to provide cardiological interventions are those where the
climate is extremely hostile and the population is concentrated in a
few single industry settlements, based on hydrocarbon or mineral
extraction. Yet, even in Moscow delays in reaching hospital are not
uncommon, with a 2013 study reporting the median delay between
onset of symptoms and a request for medical aid to be 2.4 h and
from symptom onset to hospitalization to be 4.3 h [31]. Second, a
cardiac service providing optimal care should offer primary revas-
cularisation 24 h a day and seven days a week and, in many health
facilities, patients must be transferred elsewhere for revascularisa-
tion and, even in those facilities, services are often only provided
during working hours.
This paper represents a ﬁrst step in undertaking the type of
research on geographical variations in health care in the Rus-
sian Federation that is well established in other countries. It
demonstrates the tremendous potential for undertaking natural
experiments to assess the impact of health policy at a regional level.
These ﬁndings are being used to inform an ongoing study that is
looking in detail at the management of individual patients with
myocardial infarction in 15 cities across Russia, collecting infor-
mation on their health seeking behaviour and experiences prior to
admission, their clinical management in-hospital, and the care that
they receive in the subsequent year. This research is needed; judged
by progress in reducing deaths amenable to health care, the Soviet
Union failed to beneﬁt from western medical advances during the
1970s and 1980s [32] and recent research shows the great potential
for health and corresponding economic gains from improved care,
such as better management of hypertension [33,34].
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Our current programme of research, while only a beginning, will
provide a unique resource for understanding variation in the man-
agement of cardiovascular disease in Russia and help to build much
needed capacity in health systems research in Russia.
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